Thoughts on Drug Regulatory Science in the New Era

doi:10.19803/j.1672-8629.2020.04.01

Chinese Journal of Pharmacovigilance ›› 2020, Vol. 17 ›› Issue (4): 193-197.
DOI: 10.19803/j.1672-8629.2020.04.01

Previous Articles Next Articles

Thoughts on Drug Regulatory Science in the New Era

MAO Zhenbin^1*, WANG Ying^1,2, WANG Siming^1,3

1 National Medical Products Administration, Beijing 100037, China;
2 National Institutes for Food and Drug Control, Beijing 100050, China;
3 Shenzhen Institute for Drug Control, Shenzhen Guangdong 518057, China

Received:2020-02-25 Revised:2020-06-28 Online:2020-04-15 Published:2020-04-10

Abstract

Abstract: This paper describes the course of development and significance of regulatory science, and attempts in-depth thinking about the application of drug regulatory science in China in the new era. We discussed the birth and beginning of regulatory science, the development and achievement of drug regulatory science, the essence and characteristic of regulatory science, the effect and duty of regulatory science. Through the study of the strategies and implementation method path, this paper specifies the direction in which the regulatory science systems for Traditional Chinese medicine and modern pharmaceuticals of the world level are to be established.

Key words: regulatory science, study and innovate, characteristic and effect, regulatory science system with Chinese characteristics

CLC Number:

R951

MAO Zhenbin, WANG Ying, WANG Siming. Thoughts on Drug Regulatory Science in the New Era[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 193-197.

References

[1] 杨悦. 监管科学的起源[J]. 中国食品药品监管,2019(4):13-23.
[2] 赵嘉,谭德讲,高泽诚,等.监管科学的起源定义及作用[J]. 中国药事,2014,28(12):1290-1293.
[3] Weinberg AM.Science and Trans-science[J].Minerva,1972(10):209-222.
[4] 刘昌孝. 国际药品监管科学发展概况[J]. 药物评价研究,2017,40(8):1029-1043.
[5] Wikipedia.Regulatory science[EB/OL].(2017-06-17)[2020-01-06].https://en.wikipedia.org/ wiki/Regulatory_science.
[6] Kurihara C, Saio T.What is the Regulatory Science? Concept andHistory in United States and in Japan - Interview with ProfessorSheila Jasanoff[J]. Chin Eval,2011,39(1):1-16.
[7] 川西徹. 先端的医薬品の開発に向けたレギュラトリーサイエンス研究[J]. 日薬理誌, 2016(148):272-277.
[8] 内山充. RegulatoryScience [N]. 衛研支部ニュース(全厚生職員労働組合国立衛生研究所支部),1987(272).
[9] Moghissi AA,et al.Ruckelshaus Effect[J]. Synesis: A Journal ofScience, Technology,Ethics,And Policy,2012,3(1):G6-G13.
[10] Jasanoff S.TheFifthBranch: ScienceAdvisorsasPolicymakers [M].Harvard University Press,1990:80.
[11] 张怡,王晨光.监管科学的兴起及其对各国药品监管的影响[J].中国食品药品监管,2019(7):21-29.
[12] FDA. Advancing Regulatory Science at FDA: A Strategic Plan [R].Marryland:FDA, 2011.
[13] FDA. Advancing Regulatory Science at FDA: A Strategic Plan [R].Marryland:FDA, 2011.
[14] EMA. Regulatory Science to 2025: Strategic reflection[R].EMA, 2018.
[15] FDA.Food and Drug Administration Safety and Innovation Act.21USC 301[EB/OL].(2012-08-10)[2020-01-06].https://www.fda.gov/safety.
[16] FDA. Strategy and Implementation Plan for Advancing RegulatoryScience[R]. Marryland:FDA, 2013.
[17] FDA. FY 2013-2014 Regulatory Science Progress Report[R].Marryland:FDA, 2014.
[18] De Vries C.EMA support to and involvement in regulatory science-HCPWP workshop on the framework of collaboration withacademia [R]. EMA, 2016.
[19] Kurihara C,Saio T.What is the Regulatory Science? Conceptand History in United States and in Japan-Interview withProfessor Sheila Jasanoff[J]. Chin Eval,2011,39(1):1-16.

Thoughts on Drug Regulatory Science in the New Era

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 5

Recommended Articles

Metrics

[1]	ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang. Applicability of patient registry research to regulation of medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
[2]	ZHAO Yan, LI Dong, CHENG Yinjie, JIANG Bin, ZHAO Yifei, DONG Fang, YUAN Jing. Advances in studies on post-market safety data sources and signal detection for medical devices [J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 236-240.
[3]	SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu. Research and reflection on regulatory science developments of U.S. FDA [J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
[4]	MAO Zhenbin, LIU Shuyu. Implications of Regulatory Science for the Construction of Medical Device Vigilance Systems [J]. Chinese Journal of Pharmacovigilance, 2021, 18(7): 601-605.
[5]	HUANG Xiankai, DONG Yinmao, MENG Hong, ZUO Min, HE Yifan, MENG Yuxi, JIA Yan. International Cooperation on Cosmetics Regulation Promotes Regulatory Science Internationalization of Cosmetic [J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 401-405.